LAPTM4B and head and neck squamous cell carcinoma: Since high LAPTM4B-35 expression is associated with advanced tumour stage and significantly worse DFS as well as a higher recurrence rate, LAPTM4B-35 could serve as a negative prognostic marker in patients with HNSCC.